Therefore, targeting the circ-YES1–miR-142-3p–HMGB1 axis represents a new approach in the treatment of NSCLC, and our results support the application of circ-YES1 probability as a new prognostic marker in this disease. This evidence concerns the gene HMGB1 and non-small cell lung carcinoma.